📅Journée mondiale contre le #cancer ❓Le dexrazoxane peut‐il prévenir ou réduire la cardiotoxicité des anthracyclines chez les adultes et les enfants atteints de cancer ? 📚Nouvelle revue évaluant les données probantes de 13 ECR ➡️https://t.co/ypK6wCmYih
デクスラゾキサン(dexrazoxane)はアントラサイクリン(anthracyclines)を使用している成人および小児のがん患者の心臓障害を予防または軽減できるか? https://t.co/eiQ81ucak7
Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines https://t.co/0IcKOSycBh
RT @cochrane_nz: Can the medicine dexrazoxane prevent or reduce heart damage in adults and children with cancer receiving anthracyclines?…
RT @cochrane_nz: Can the medicine dexrazoxane prevent or reduce heart damage in adults and children with cancer receiving anthracyclines?…
RT @cochrane_nz: Can the medicine dexrazoxane prevent or reduce heart damage in adults and children with cancer receiving anthracyclines?…
Can the medicine dexrazoxane prevent or reduce heart damage in adults and children with cancer receiving anthracyclines? Read @Cochrane_GNOCG's latest #CochraneSystematicReview! 🧠 🌐 https://t.co/ZZmb8kdE11 👥 @CancerSocietyNZ https://t.co/ZuFp2H7eis
"If risk of cardiac damage is high, it might be justified to use dexrazoxane in children or adults with cancer treated with anthracyclines... Possible risk of adverse effects, including secondary malignant neoplasias" should be considered https://t.co/vBTm
Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines - de Baat, EC - 2022 | Cochrane Library https://t.co/6EqhiCfzTP https://t.co/SQ3gKoubWO
Can the medicine dexrazoxane prevent or reduce heart damage in adults and children with cancer receiving anthracyclines? https://t.co/dKzbZlyJqz